5:25 PM
 | 
Oct 30, 2013
 |  BC Extra  |  Clinical News

Merrimack slides on ovarian cancer data

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) fell $0.64 (19%) to $2.74 on Wednesday after reporting that MM-121 plus paclitaxel missed the primary endpoint of improving progression-free survival (PFS) vs. paclitaxel alone in a Phase II trial to treat platinum-resistant or refractory advanced ovarian cancer. In August,...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >